1.
|
10 p, 3.3 MB |
Feasibility and outcomes after dose reduction of immunochemotherapy in young adults with Burkitt lymphoma and leukemia : results of the BURKIMAB14 trial
/
Ribera, Josep Maria (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Morgades, Mireia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Garcia-Calduch, Olga (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Sirvent, Maialen (Hospital Universitario de Donostia) ;
Buendia, Buenaventura (Hospital Universitario 12 de Octubre) ;
Cervera, Marta (Institut Catala d'Oncologia-Hospital Joan XXIII) ;
Luzardo, Hugo (Hospital Universitario de Gran Canaria Dr. Negrin) ;
Hernandez-Rivas, Jesus Maria (Hospital Universitario de Salamanca) ;
Sitges, Marta (Hospital Universitari de Girona Doctor Josep Trueta) ;
Garcia-Cadenas, Irene (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Abrisqueta, Pau (Hospital Universitari Vall d'Hebron) ;
Montesinos, Pau (Hospital Universitari i Politècnic La Fe (València)) ;
Bastos-Oreiro, Mariana (Hospital General Universitario Gregorio Marañón) ;
De Llano, Maria Paz Queipo (Hospital Universitario Virgen de la Victoria (Màlaga, Andalusia)) ;
Bravo, Pilar (Hospital Universitario de Fuenlabrada. Madrid) ;
Torrent, Anna (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Herrera, Pilar (Hospital Universitario Ramon y Cajal) ;
Garcia-Guinon, Antonni (Hospital Universitari Arnau de Vilanova) ;
Vall-Llovera, Ferran (Hospital Universitari MútuaTerrassa) ;
Serrano, Josefina (Hospital Universitario Reina Sofía (Córdoba, Espanya)) ;
Terol, Maria José (Hospital Clinico Universitario de Valencia) ;
Bergua, Juan Miguel (Hospital San Pedro de Alcántara) ;
Garcia-Noblejas, Ana (Hospital Universitario de La Princesa) ;
Barrenetxea, Cristina (Hospital Universitario Basurto) ;
Llorente, Laura (Hospital Universitario HM Sanchinarro) ;
Garcia-Belmonte, Daniel (Hospital Universitario La Zarzuela) ;
Gimeno, Eva (Hospital del Mar (Barcelona, Catalunya)) ;
Cladera, Antonia (Hospital Universitari Son Llatzer) ;
Mercadal, Santiago (Institut Català d'Oncologia) ;
Sancho, Juan Manuel (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
High dose-intensive or infusional intermediate-dose immunochemotherapy is highly effective treatment for Burkitt lymphoma irrespective of human immunodeficiency virus (HIV) infection. However, toxicities of these regimens are relevant, especially in older adults and elderly patients. [...]
2024 - 10.3324/haematol.2023.283342
Haematologica, Vol. 109 Núm. 2 (january 2024) , p. 543-552
|
|
2.
|
7 p, 660.3 KB |
Clinical characteristics of patients with central nervous system relapse in BCR-ABL1-positive acute lymphoblastic leukemia : the importance of characterizing ABL1 mutations in cerebrospinal fluid
/
Sanchez, R. (Hospital 12 de Octubre (Madrid)) ;
Ayala, Rosa (Hospital 12 de Octubre (Madrid)) ;
Alonso, R.A. (Hospital 12 de Octubre (Madrid)) ;
Martínez, M.P. (Hospital 12 de Octubre (Madrid)) ;
Ribera, Jordi (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
García, Olga (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Sanchez-Pina, J. (Hospital 12 de Octubre (Madrid)) ;
Mercadal, S. (ICO-Hospital Duran i Reynals (Bellvitge)) ;
Montesinos, P. (Hospital Universitari i Politècnic La Fe de València) ;
Martino Bofarull, Rodrigo (Institut d'Investigació Biomèdica Sant Pau) ;
Barba, Pere (Hospital Universitari Vall d'Hebron) ;
González-Campos, J. (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Barrios, M. (Hospital Regional Universitario Carlos Haya (Málaga)) ;
Lavilla, E. (Hospital Universitario Lucus Augusti (Lugo)) ;
Gil, C. (Hospital General Universitario de Alicante (Alacant, País Valencià)) ;
Bernal, T. (Hospital Universitario Central de Asturias) ;
Escoda, L. (Hospital Universitari Joan XXIII de Tarragona) ;
Abella Monreal, Eugenia (Hospital del Mar (Barcelona, Catalunya)) ;
Amigo, María-Luz (Hospital General Universitario Morales Meseguer (Múrcia)) ;
Moreno, M.J. (Hospital Universitario Virgen de la Victoria (Màlaga, Andalusia)) ;
Bravo, P. (Hospital de Fuenlabrada) ;
Guàrdia, R. (Hospital Universitari de Girona Doctor Josep Trueta) ;
Hernández-Rivas, J.M. (Hospital Universitario de Salamanca) ;
García-Guiñón, A. (Hospital Universitari Arnau de Vilanova) ;
Piernas, Sonia (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Ribera, José Maria (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Martínez-López, J. (Hospital 12 de Octubre (Madrid)) ;
Universitat Autònoma de Barcelona
We investigated the frequency, predictors, and evolution of acute lymphoblastic leukemia (ALL) in patients with CNS relapse and introduced a novel method for studying BCR-ABL1 protein variants in cDNA from bone marrow (BM) and cerebrospinal fluid (CSF) blast cells. [...]
2017 - 10.1007/s00277-017-3002-1
Annals of Hematology, Vol. 96 Núm. 7 (january 2017) , p. 1069-1075
|
|
3.
|
17 p, 1.2 MB |
Ponatinib vs. Imatinib as Frontline Treatment for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia : A Matching Adjusted Indirect Comparison
/
Ribera, Jose-Maria (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Prawitz, Thibaud (Evidera Inc) ;
Freitag, Andreas (Evidera Inc) ;
Sharma, Anuj (Evidera Inc) ;
Dobi, Balázs (Evidera Inc) ;
Rizzo, Federica (Incyte Biosciences International Sàrl, Morges, Switzerland) ;
Sabatelli, Lorenzo (Incyte Biosciences International Sàrl, Morges, Switzerland) ;
Patos, Petros (Incyte Biosciences International Sàrl, Morges, Switzerland)
Introduction: Efficacy of ponatinib-based treatment for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL) has not been compared to imatinib-based treatments in head-to-head clinical trials. [...]
2023 - 10.1007/s12325-023-02497-y
Advances in Therapy, Vol. 40 Núm. 7 (july 2023) , p. 3087-3103
|
|
4.
|
|
5.
|
10 p, 786.4 KB |
Haploidentical transplantation is associated with better overall survival when compared to single cord blood transplantation : An EBMT-Eurocord study of acute leukemia patients conditioned with thiotepa, busulfan, and fludarabine
/
Giannotti, Federica (Saint-Antoine Hospital) ;
Labopin, Myriam (Hôpital Saint-Antoine (Paris, França)) ;
Shouval, Roni (Chaim Sheba Medical Center (Israel)) ;
Sanz, Jaime (Instituto de Salud Carlos III) ;
Arcese, William (Rome Transplant Network tor Vergatä) ;
Angelucci, Emanuele (Ospedale Policlinico San Martino) ;
Malouf Sierra, Jorge 1971- (Institut d'Investigació Biomèdica Sant Pau) ;
Ribera, Jose-Maria (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Santarone, Stella (Ospedale Civile) ;
Benedetto, Bruno (S.S.C.V.D Trapianto di Cellule Staminali A.O.U Citta della Salute e della Scienza di Torino) ;
Rambaldi, Alessandro (Azienda Ospedaliera Papa Giovanni XXIII) ;
Saccardi, Riccardo (Azienda Ospedaliera Universitaria Careggi) ;
Blaise, Didier (Institut Paoli Calmettes) ;
Carella, Michele Angelo (IRCCS) ;
Rocha, Vanderson (Universidade de São Paulo) ;
Baron, Frederic (University of Liege) ;
Mohty, Mohamad (Hospital Saint- Antoine) ;
Ruggeri, Annalisa (Ospedale Pediatrico Bambino Gesù (Roma, Itàlia)) ;
Nagler, Arnon (Tel-Aviv University) ;
Universitat Autònoma de Barcelona
Thiotepa-busulfan-fludarabine (TBF) is a widely used conditioning regimen in single umbilical cord blood transplantation (SUCBT). More recently, it was introduced in the setting of non-T cell depleted haploidentical stem cell transplantation (NTD-Haplo). [...]
2018 - 10.1186/s13045-018-0655-8
Journal of hematology & oncology, Vol. 11 Núm. 1 (30 2018) , p. 110
|
|
6.
|
12 p, 1.1 MB |
Genomics improves risk stratification of adults with T-cell acute lymphoblastic leukemia enrolled in measurable residual disease-oriented trials
/
González-Gil, Celia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Morgades, Mireia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Lopes, Thaysa (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Fuster-Tormo, Francisco (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
García-Chica, Jesús (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Zhao, Ran (Cleveland Clinic) ;
Montesinos, Pau (Hospital Universitari i Politècnic La Fe (València)) ;
Torrent Catarineu, Anna (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Díaz-Beyá, Marina (Hospital Clínic i Provincial de Barcelona) ;
Coll, Rosa (Institut Català d'Oncologia) ;
Hermosín, Lourdes (Hospital de Jerez) ;
Mercadal, Santiago (Hospital Duran i Reynals-ICO (Hospitalet del Llobregat)) ;
González-Campos, José (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Zamora, Lurdes (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Artola, Teresa (Hospital de Donostia (Sant Sebastià, País Basc)) ;
Vall-Llovera, Ferran (Hospital Universitari MútuaTerrassa (Terrassa, Catalunya)) ;
Tormo, Mar (Instituto de Investigación Sanitaria (València)) ;
Gil-Cortés, Cristina (Hospital General de Alicante (Alicante)) ;
Barba, Pere (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Novo, Andrés (Hospital Universitari Son Espases (Palma de Mallorca, Balears)) ;
Ribera Salas, Jordi (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Bernal, Teresa (Hospital Universitario Central de Asturias) ;
de Ugarriza, Paula López (Hospital Universitario Central de Asturias) ;
Queipo, María-Paz (Hospital Universitario Virgen de la Victoria (Màlaga, Andalusia)) ;
Martínez-Sánchez, Pilar (Hospital Universitario 12 de Octubre (Madrid)) ;
Giménez, Alicia (Hospital Universitario 12 de Octubre (Madrid)) ;
González-Martínez, Teresa (Hospital Universitario de Salamanca) ;
Cladera, Antonia (Hospital Universitari Son Llàtzer (Palma de Mallorca, Balears)) ;
Cervera, José (Hospital Universitari i Politècnic La Fe (València)) ;
Fernández-Martín, Rosa (Hospital Universitario Insular de Gran Canaria) ;
Ardaiz, María Ángeles (Complejo Hospitalario de Navarra) ;
Vidal, María Jesús (Complejo Hospitalario de León) ;
Baena, Ángela (Complejo Hospitalario de Jaén) ;
López-Bigas, Nuria (Institut de Recerca Biomèdica (Barcelona)) ;
Bigas Salvans, Anna (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Maciejewski, Jaroslaw (Taussig Cancer Institute) ;
Orfao, Alberto (Universidad de Salamanca) ;
Ribera, Jose-Maria (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Genescà, Eulàlia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Universitat Autònoma de Barcelona
Genetic information has been crucial to understand the pathogenesis of T-cell acute lymphoblastic leukemia (T-ALL) at diagnosis and at relapse, but still nowadays has a limited value in a clinical context. [...]
2022 - 10.3324/haematol.2022.281196
Haematologica, Vol. 108 (november 2022) , p. 969-980
|
|
7.
|
6 p, 2.8 MB |
HHV8 and EBV-negative primary effusion-based lymphoma : A case report of a new provisional entity and review of literature
/
Canelo-Vilaseca, Marta (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Tapia, Gustavo (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Orna, Elisa (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Sorigue, Marc (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Granada, Isabel (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Palomar-Muñoz, Azahara (Hospital Universitari de Bellvitge) ;
Castillo, Ana (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Grau Cat, Javier (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Mesa Tudel, Alba (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Ribera, Jose-Maria (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Sancho, Juan-Manuel (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Navarro, José-Tomás (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
HHV8- and EBV-negative primary effusion lymphoma is an extremely rare neoplasm involving body cavities without detectable tumor mass. It usually presents in elderly patients without known immunodeficiency. [...]
2023 - 10.1002/ccr3.7282
Clinical Case Reports, Vol. 11 (may 2023)
|
|
8.
|
|
9.
|
14 p, 1.0 MB |
CD34 + CD19 − CD22 + B-cell progenitors may underlie phenotypic escape in patients treated with CD19-directed therapies
/
Bueno, Clara (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Barrera, Susana (Universidad de Salamanca) ;
Bataller, Alex (Hospital Clínic i Provincial de Barcelona) ;
Ortiz-Maldonado, Valentín (Hospital Clínic i Provincial de Barcelona) ;
Elliot, Natalina (John Radcliffe Hospital (Oxford, Regne Unit)) ;
O'Byrne, Sorcha (John Radcliffe Hospital (Oxford, Regne Unit)) ;
Wang, Guanlin (University of Oxford) ;
Rovira, Montse (University of Oxford) ;
Gutiérrez-Agüera, Francisco (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Trincado Alonso, Juan Luis, 1987- (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
González-González, María (Universidad de Salamanca) ;
Morgades, Mireia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Sorigue, Marc (Universitat Autònoma de Barcelona) ;
Bárcena, Paloma (Universidad de Salamanca) ;
Zanetti, S. R (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Torrebadell, Montse (Hospital Sant Joan de Déu (Barcelona, Catalunya)) ;
Vega-Garcia, Nerea (Hospital Sant Joan de Déu (Barcelona, Catalunya)) ;
Rives, Susana (Hospital Sant Joan de Déu (Barcelona, Catalunya)) ;
Mallo, Maria del Mar (Universitat Autònoma de Barcelona) ;
Sole, F (Universitat Autònoma de Barcelona) ;
Mead, Adam J. (Centro Nacional de Investigaciones Oncológicas Carlos III (Espanya)) ;
Roberts, Irene (Oxford Biomedical Research Centre) ;
Thongjuea, Supat (Hospital Sant Joan de Déu (Barcelona, Catalunya)) ;
Psaila, Bethan (Oxford Biomedical Research Centre) ;
Juan, Manel (Hospital Clínic i Provincial de Barcelona) ;
Delgado, Julio (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Urbano-Ispizúa, Alvaro (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Ribera, Jose-Maria (Universitat Autònoma de Barcelona) ;
Orfao, Alberto (Universidad de Salamanca) ;
Roy, Anindita (Oxford Biomedical Research Centre) ;
Menéndez Bujan, Pablo (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Three article in this issue present preclinical data aimed at improving immunotherapeutic approaches for relapsed B- and T-cell acute lymphoblastic leukemia (T-ALL). Chimeric antigen receptor T (CAR-T) cell therapy directed against relapsed T-ALL is hampered by difficulty in identifying a target antigen that is not also expressed on healthy T cells, risking "fratricide" with T-cell aplasia and loss of the CAR-T cells. [...]
2022 - 10.1182/blood.2021014840
Blood, Vol. 140 (july 2022) , p. 38-44
|
|
10.
|
9 p, 1.5 MB |
Outcome of COVID-19 in allogeneic stem cell transplant recipients : Results from the EPICOVIDEHA registry
/
Busca, Alessandro (AOU Citta' della Salute e della Scienza) ;
Salmanton-García, Jon (University of Cologne) ;
Marchesi, Francesco (IRCCS Regina Elena National Cancer Institute) ;
Farina, Francesca (IRCCS Ospedale San Raffaele) ;
Seval, Guldane Cengiz (Ankara University) ;
Van Doesum, Jaap (University Medical Center Groningen) ;
De Jonge, Nick (Amsterdam UMC) ;
Bahr, Nathan C. (University of Kansas Medical Center) ;
Maertens, Johan (K.U. Leuven and Department of Hematology) ;
Meletiadis, Joseph ("Attikon" University General Hospital) ;
Fracchiolla, Nicola (Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico) ;
Weinbergerová, Barbora (Department of Internal Medicine - Hematology and Oncology, Masaryk University Hospital Brno) ;
Verga, Luisa (Università Milano-Bicocca) ;
Ráčil, Zdeněk (Institute of Hematology and Blood Transfusion) ;
Jiménez, Moraima (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Glenthøj, Andreas (Copenhagen University Hospital) ;
Blennow, Ola (Karolinska University Hospital and Karolinska Institutet (Suècia)) ;
Tanase, Alina Daniela (University of Medicine and Pharmacy Carol Davila) ;
Schönlein, Martin (University Medical Center Hamburg-Eppendorf. Department of Oncology, Hematology and Bone Marrow Transplantation) ;
Prezioso, Lucia (Hospital University of Parma - Hematology and Bone Marrow Unit) ;
Khanna, Nina (University Hospital Basel (Basilea, Suïssa)) ;
Duarte, Rafael (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
Žák, Pavel (University Hospital Hradec Kralove (República Txeca)) ;
Nucci, Marcio (Federal University of Rio de Janeiro) ;
Machado, Marina (Hospital General Universitario Gregorio Marañón) ;
Kulasekararaj, Austin (King's College London) ;
Espigado, Ildefonso (Instituto de Biomedicina de Sevilla) ;
De Kort, Elizabeth (Radboudumc) ;
Ribera-Santa Susana, José-María (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Marchetti, Monia (Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo) ;
Magliano, Gabriele (ASST Grande Ospedale Metropolitano Niguarda) ;
Falces-Romero, Iker (Hospital Universitario La Paz (Madrid)) ;
Ilhan, Osman (Ankara University) ;
Ammatuna, Emanuele (University Medical Center Groningen) ;
Zompi, Sofia (Stem Cell Transplant Center, AOU Citta' della Salute e della Scienza) ;
Tsirigotis, Panagiotis (National and Kapodistrian University of Athens. "Attikon" University General Hospital) ;
Antoniadou, Anastasia (National and Kapodistrian University of Athens. "Attikon" University General Hospital) ;
Zambrotta, Giovanni (Università Milano-Bicocca) ;
Nordlander, Anna (Department of Infectious Diseases, Karolinska University Hospital) ;
Karlsson, Linda Katharina (University of Copenhagen) ;
Hanakova, Michaela (Institute of Hematology and Blood Transfusion) ;
Dragonetti, Giulia (Fondazione Policlinico Universitario Agostino Gemelli - IRCCS) ;
Cabirta, Alba (Vall d'Hebron Institut d'Oncologia) ;
Berg Venemyr, Caroline (Copenhagen University Hospital - Rigshospitalet) ;
Gräfe, Stefanie (University of Cologne) ;
Van Praet, Jens (AZ Sint-Jan Brugge-Oostende AV. Department of Nephrology and Infectious diseases) ;
Tragiannidis, Athanasios (Aristotle University of Thessaloniki) ;
Petzer, Verena (Medical University of Innsbruck. Department of Hematology and Oncology) ;
López-García, Alberto (Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz (Madrid)) ;
Itri, Federico (San Luigi Gonzaga Hospital - Orbassano) ;
Groh, Ana (Infektiologie, Universitätsklinikum Frankfurt am Main) ;
Gavriilaki, Eleni (General Hospital of Thessaloniki "George Papanikolaou") ;
Dargenio, Michelina (Hematology and Stem Cell Transplant Unit) ;
Rahimli, Laman (University of Cologne) ;
Cornely, Oliver A. (German Centre for Infection Research (DZIF)) ;
Pagano, Livio (Università Cattolica del Sacro Cuore)
The outcome of COVID-19 in allogeneic hematopoietic stem cell transplantation (HSCT) recipients is almost uniformely considered poor. The aim of present study was to retrospectively analyse the outcome and risk factors for mortality in a large series of patients who developed COVID-19 infection after an allogeneic HSCT. [...]
2023 - 10.3389/fimmu.2023.1125030
Frontiers in immunology, Vol. 14 (february 2023)
|
|